Primary Aldosteronism Due to Aldosterone Producing Adenoma
13
1
2
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (13)
Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)
11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours
Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism
Spatial Proteomics Profiles of Aldosterone-producing Adenoma and Unilateral Hyperplasia
Prospective Study Assessing Blood Pressure and Other Outcomes Post-treatment in Patients With Primary Aldosteronism
First-in-human Evaluation of [18F]CETO
Outcome of Patients With Primary Aldosteronism
Primary Aldosteronism and Surgically Curable Forms in Hypertension Patients Using 11C-Metomidate
Predicting Reduction of Hypertension After Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis
Renal Sympathetic Denervation From The Adventitia on Hypertension
Ipsilateral and Contralateral Index for the Interpretation of Adrenal Vein Sampling (AVS) in Primary Aldosteronism
MRA and ARB Treatment in Screening of Primary Aldosteronism
Rapid Cortisol Assay in Adrenal Vein Sampling